What is GLP-1 in the human body?
Before the Gila monster, there was the human gut. GLP-1 — glucagon-like peptide-1 — is a hormone produced naturally in the L-cells of the small intestine and colon, released in response to food intake. It performs three primary jobs: it signals satiety to the brain (suppressing appetite), slows gastric emptying (so food is processed more gradually), and enhances insulin secretion in a glucose-dependent fashion (only when blood sugar is already elevated, which reduces hypoglycemia risk).
The problem with native GLP-1 from a drug development standpoint: it is extremely short-lived. An enzyme called dipeptidyl peptidase-4 (DPP-4) degrades active GLP-1 within 1 to 2 minutes of entering the bloodstream. A hormone with a two-minute window is impossible to use therapeutically as a once-daily or once-weekly drug. Researchers needed a molecule that could activate the GLP-1 receptor but survive long enough to matter.
The Gila monster discovery
In 1992, endocrinologist Dr. John Eng, working at the Veterans Affairs Medical Center in the Bronx, was studying the venom of the Heloderma suspectum — the Gila monster, a venomous lizard native to the American Southwest and Mexico. Dr. Eng had a hypothesis that unusual hormones might be found in unusual places. He was right.
In Gila monster saliva, he identified a peptide he called exendin-4. Its amino acid sequence was approximately 53% identical to human GLP-1— a significant structural similarity suggesting it might activate the same receptor. But unlike native GLP-1, exendin-4 was resistant to DPP-4 degradation. Its half-life was measured in hours, not minutes.
This is the moment that launched a drug class. A compound that activated the GLP-1 receptor but wasn’t rapidly degraded was the pharmacological foundation researchers had been looking for.
A peptide in Gila monster saliva, ~53% identical to human GLP-1 but resistant to rapid breakdown, launched an entire drug class.
Why does the Gila monster have a GLP-1-like compound in its saliva?
The most plausible evolutionary explanation relates to the Gila monster’s unusual feeding biology. These lizards eat infrequently — sometimes only a handful of large meals per year — and they store energy in their tails. When they do eat, they consume very large quantities relative to their body size.
A more durable GLP-1-like signal would make physiological sense in this context: a sustained insulin regulatory response that can manage the metabolic demands of a very large, infrequent meal. The exendins may have evolved precisely because the typical mammalian GLP-1 system — adapted for frequent smaller meals — wasn’t adequate for the Gila monster’s eating pattern.
This is speculative evolutionary biology, not confirmed mechanism — but it is the leading hypothesis and it makes biological sense.
How did the discovery become exenatide, the first GLP-1 drug?
Dr. Eng’s discovery sat without pharmaceutical backing for nearly a decade. He eventually licensed the discovery to Amylin Pharmaceuticals, which collaborated with Eli Lilly to develop a synthetic version of exendin-4. That compound, exenatide, was approved by the FDA in 2005 under the brand name Byetta — the first GLP-1 receptor agonist approved for use in humans, initially for type 2 diabetes management.
Exenatide required twice-daily injection because even with its DPP-4 resistance, its half-life was measured in hours. A longer-acting weekly formulation, Bydureon, followed in 2012.
The drug class that exenatide established attracted serious investment and research across the pharmaceutical industry. Novo Nordisk developed liraglutide (a GLP-1 analogue modified from human GLP-1 rather than from exendin-4), approved for diabetes in 2010. They then engineered semaglutide — a further-modified GLP-1 analogue with a half-life of approximately one week — approved for diabetes in 2017 and for weight management in 2021.
How do semaglutide and tirzepatide relate to the Gila monster discovery?
Semaglutide is not derived from Gila monster venom. It is a synthetic molecule built on a modified human GLP-1 sequence — 94% identical to human GLP-1, with key modifications that extend its half-life and allow weekly dosing. The Gila monster’s contribution was conceptual: proving that a DPP-4-resistant GLP-1 receptor agonist could work. Semaglutide is the product of a separate engineering lineage.
Tirzepatide (Eli Lilly’s Mounjaro / Zepbound) takes the concept further: it is a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone with metabolic effects. The dual mechanism accounts for the larger average weight loss seen in tirzepatide trials compared to GLP-1-only agents.
Neither compound has any biological origin in a lizard. But neither would likely exist without John Eng’s afternoon with Gila monster saliva in a Bronx laboratory in 1992.
Compounded GLP-1 agents: what they are
Compounded semaglutide and tirzepatide — available through clinician-supervised programs like PepScribe — are fully synthetic molecules prepared by licensed 503A compounding pharmacies in the USA. They are not FDA-approved drugs and are not the same as branded Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded versions are individualized preparations made to a clinician’s specification for a specific patient.
No Gila monsters involved. No hidden overseas supply chain.
Frequently asked questions
Is GLP-1 really derived from the Gila monster?
The modern GLP-1 drugs are not derived from Gila monster venom. But the discovery pathway started there: in the 1980s, researchers found that exendin-4, a peptide in Heloderma suspectum saliva, had a structure similar to human GLP-1 and activated the same receptor. This led to the drug exenatide (Byetta) — the first GLP-1 receptor agonist approved for human use. Semaglutide and tirzepatide are synthetic molecules designed to work on the same receptor via a separate development pathway.
What is GLP-1 and where does it come from in the human body?
GLP-1 (glucagon-like peptide-1) is a hormone produced in the L-cells of the small intestine in response to eating. It signals satiety to the brain, slows gastric emptying, and enhances insulin secretion in a glucose-dependent manner. The human GLP-1 peptide is very short-lived in the bloodstream — degraded within minutes by an enzyme called DPP-4. GLP-1 drugs are engineered to resist this rapid degradation.
How does semaglutide relate to the Gila monster discovery?
Semaglutide is not derived from exendin-4 or Gila monster venom. It is a synthetic GLP-1 analogue developed by Novo Nordisk, engineered by modifying human GLP-1 to extend its half-life to approximately one week. The Gila monster connection is to exenatide and liraglutide (earlier GLP-1 drugs), not to semaglutide specifically.
Why does the Gila monster have a GLP-1-like compound in its saliva?
The leading hypothesis is that exendin-4 evolved to function as a digestive hormone in the Gila monster's unusual physiology — these lizards eat infrequently and in very large meals, and the exendin-4 compounds may help regulate their insulin response to those large food intakes. The Gila monster's slow metabolism and intermittent feeding may have driven the evolution of a more durable GLP-1-like signal.
What happened after the Gila monster discovery?
Dr. John Eng's discovery of exendin-4 in 1992 led to the development of exenatide (approved by the FDA in 2005). This opened the GLP-1 receptor agonist drug class, which subsequently yielded liraglutide, semaglutide, tirzepatide, and others — a class now central to both type 2 diabetes management and weight management.
Does compounded semaglutide come from Gila monsters?
No. Compounded semaglutide is a fully synthetic molecule produced through peptide synthesis. It has no biological origin from Gila monsters or their venom. It is prepared by licensed 503A compounding pharmacies in the USA under clinician supervision.